347 related articles for article (PubMed ID: 29509898)
1. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
3. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
7. CBAP regulates the function of Akt-associated TSC protein complexes to modulate mTORC1 signaling.
Liao WT; Chiang YJ; Yang-Yen HF; Hsu LC; Chang ZF; Yen JJY
J Biol Chem; 2023 Dec; 299(12):105455. PubMed ID: 37949232
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ERK1/2 Restores GSK3β Activity and Protein Synthesis Levels in a Model of Tuberous Sclerosis.
Pal R; Bondar VV; Adamski CJ; Rodney GG; Sardiello M
Sci Rep; 2017 Jun; 7(1):4174. PubMed ID: 28646232
[TBL] [Abstract][Full Text] [Related]
9. A new homozygous HERC1 gain-of-function variant in MDFPMR syndrome leads to mTORC1 hyperactivation and reduced autophagy during cell catabolism.
Schwarz JM; Pedrazza L; Stenzel W; Rosa JL; Schuelke M; Straussberg R
Mol Genet Metab; 2020; 131(1-2):126-134. PubMed ID: 32921582
[TBL] [Abstract][Full Text] [Related]
10. Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Filippakis H; Belaid A; Siroky B; Wu C; Alesi N; Hougard T; Nijmeh J; Lam HC; Henske EP
Sci Rep; 2018 Sep; 8(1):14161. PubMed ID: 30242175
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).
Liu HJ; Lam HC; Baglini CV; Nijmeh J; Cottrill AA; Chan SY; Henske EP
Oncogene; 2019 Dec; 38(49):7367-7383. PubMed ID: 31420607
[TBL] [Abstract][Full Text] [Related]
12. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
13. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
Jones AT; Narov K; Yang J; Sampson JR; Shen MH
Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
[TBL] [Abstract][Full Text] [Related]
16. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 mediates PSAT1 expression and serine metabolism in TSC2-deficient cells.
Wang J; Filippakis H; Hougard T; Du H; Ye C; Liu HJ; Zhang L; Hindi K; Bagwe S; Nijmeh J; Asara JM; Shi W; El-Chemaly S; Henske EP; Lam HC
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34544857
[TBL] [Abstract][Full Text] [Related]
18. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.
Zhang J; Kim J; Alexander A; Cai S; Tripathi DN; Dere R; Tee AR; Tait-Mulder J; Di Nardo A; Han JM; Kwiatkowski E; Dunlop EA; Dodd KM; Folkerth RD; Faust PL; Kastan MB; Sahin M; Walker CL
Nat Cell Biol; 2013 Oct; 15(10):1186-96. PubMed ID: 23955302
[TBL] [Abstract][Full Text] [Related]
19. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
20. Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice.
Peron A; Au KS; Northrup H
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):281-290. PubMed ID: 30255984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
